8 years ago

Exonate Receives £4.9 Million Grant for Wet AMD Treatment

  • Exonate, a Cambridge, UK-based biotechnology company, received a £4.9 million grant from the Wellcome Trust to continue developing an eye-drop treatment for wet age-related macular degeneration

  • The company, which recently raised £1.5 million in funding, will use the funds to optimize its small molecule inhibitors of VEGF production

  • Exonate expects to enter clinical trials in early 2020.

      • ProblemHealthcare

      "Wet age-related macular degeneration is a leading cause of vision loss in people over 50, and currently available treatments are expensive, inconvenient, and can have serious side effects."

      Solution

      "Exonate has developed small molecules that inhibit the production of VEGF, a protein that promotes blood vessel growth in the eye, through selective inhibition of SRPK1-mediated VEGF splicing. This innovative approach could lead to a more effective, safe, and convenient treatment for wet AMD."

      Covered on